Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CTLs
Cytotoxic T Lymphocytes · 1 trial · 1 indication
Safety will be measured by the absence of: Grade ≥ 3 acute infusion reactions
Safety will be measured by the absence of: Any grade 4 or higher adverse event thought to be related to the CTL therapy and outside the spectrum of identified COVID related events.
Safety will be measured by the absence of: Any manifestation of acute GVHD (for acute grades 2-4 GVHD-Glucksberg criteria) 53 resistant to 2 mg/kg of solumedrol or equivalent
Safety will be measured by the absence of: Marrow aplasia due to 3rd party engraftment
Safety will be measured by the absence of: Grade ≥ 2+ Neurotoxicity as measured by the ASTCT/ICANS consensus grading system
Safety will be measured by the absence of: Grade ≥ 2+ CRS as measured by the ASTCT Consensus Grading Criteria for CRS
| Arm | Type | Description |
|---|---|---|
| ARM A: Covid-19 Patients Receiving CTLs | EXPERIMENTAL | Patients who have an HLA antigen in common with COVID-19 fighting T cells will receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells, and then if there are no serious side effects, the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested, and each patient will complete a 14 day monitoring period before the next patient can be treated. |
| ARM B: Covid-19 Patients Not Receiving CTLs | NO_INTERVENTION | Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure, temperature, and oxygen level (pulse oximetry) at home and report this information, as well as their progress in getting over the COVID-19 infection, to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy. |
| Name | Type | Description |
|---|---|---|
| Cytotoxic T Lymphocytes | DRUG | Given IV. Cytotoxic T Lymphocytes collected from healthy volunteer donors who have recovered from COVID-19. The T cells are collected, manufactured to be COVID-specific, and stored frozen at Thomas Jefferson University. |
Inclusion Criteria: Have a documented active COVID-19 infection and one of the following high-risk criteria: * Malignancy receiving radiation or chemotherapy in the prior 24 months. * Chronic lung disease such as asthma, COPD, interstitial lung disease, pulmonary hypertension or cystic fibrosis, r...
Cytotoxic T Lymphocytes is an investigational cell-based therapy developed by Tevogen Bio Holdings Inc. for COVID-19. It consists of infection-fighting immune cells generated in the laboratory and transferred to high-risk patients with COVID-19 infection. It is being studied as a treatment for patients aged 18 years and older.
Cytotoxic T Lymphocytes is being developed for the treatment of COVID-19 in high-risk patients. The therapy involves laboratory-generated infection-fighting immune cells that are transferred to patients with COVID-19 infection. It is intended for adults 18 years and older and has been studied in a Phase 1 trial.
Cytotoxic T Lymphocytes is developed by Tevogen Bio Holdings Inc., which trades under the ticker TVGN. The company is the sponsor of the clinical program evaluating this cell therapy for COVID-19.
Cytotoxic T Lymphocytes is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The Phase 1 trial has been completed, and no active trials are currently listed for this therapy.
Cytotoxic T Lymphocytes has been evaluated in one completed Phase 1 clinical trial, NCT04765449, titled Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection. The trial enrolled 30 participants in the United States and included adults 18 years and older.